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SUMMARY
Objective: Determine the efficacy and side effects of low-frequency repetitive trans-
cranial magnetic stimulation (rTMS) to treat refractory neocortical epilepsy and study
differences in effect between a figure-8 and round coil type.
Methods: This single-center randomized sham-controlled crossover trial
(NCT01745952 on ClinicalTrials.gov) included 11 patients with well-defined focal epi-
lepsy. rTMS (0.5 Hz) was targeted to the focus during three treatment conditions con-
sisting of 1,500 stimulations/day for 10 weekdays at 90% of resting motor threshold
(rMT) followed by a 10-week observation period. Patients were randomized for the
order in which the figure-8, round, and sham coil were used. Outcome assessors and
patients were blinded to the type of coil used. The primary outcomemeasure was the
percentage of seizure reduction after active rTMS treatment. Other outcome mea-
sures were responder rate, quality of life, and side effects.
Results: There was no difference between a figure-8 and round coil. None of the
patients achieved an overall 50% seizure reduction. One patient responded during
1 month after treatment with either active coil, followed by a significant increase in
seizure frequency. Another patient had a fourfold increase in seizure frequency during
rTMS treatment.
Significance: This study provides evidence that rTMS is on average not effective for
reducing seizure frequency. No difference in effectiveness between the different coil
types was observed. It can, however, exacerbate seizures during treatment and lead to
a rebound in seizure frequency after an initial reduction.
KEY WORDS: Experimental treatment, Coil type for magnetic stimulation, Seizure
exacerbation.
Repetitive transcranial magnetic stimulation (rTMS) is a
noninvasive brain stimulation technique that can alter the
excitability of cortical regions by patterned application of a
time-varying electromagnetic field.1 Inhibitory protocols
such as low-frequency rTMS seem to hold promise for epi-
lepsy treatment. Until now, 13 studies with a total of 196
patients undergoing active treatment showed mixed
results.2–14 This could be due in part to the variability in
inclusion criteria and treatment protocols. Based on individ-
ual trials and the meta-analysis of Hsu et al.,15 it was
demonstrated that low-frequency rTMS is especially
promising for patients with cortical dysplasia or neocortical
epilepsy, if the stimulation was targeted to the epileptic
focus. rTMS aimed at the vertex was not effective,11,15
probably because the epileptogenic zone was not targeted.
rTMS of mesial temporal structures was not effective15
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because these structures are too deep to be affected directly
by rTMS.
In most studies, the target of stimulation was the most
active point in the 10-20 or 10-10 electroencephalography
(EEG) system. However, in one patient,12 the ictal EEG and
single-photon emission computerized tomography coregis-
tered to MRI (SISCOM) data were used to define the focus,
and neuronavigation was used to position the TMS coil.
This patient experienced a 90% seizure reduction. This was
the only study12 to date using neuronavigation. Treatment
protocols also differed in their stimulation frequencies and
intensities, but those differences were not clearly associated
with outcome.15 A wide range of coil types, both commer-
cially available and custom-made, have been used. The
number of rTMS pulses a day, days of treatment, and spread
of treatment sessions over time were also diverse, ranging
from 1003 to 3,00012 stimuli per day with treatments admin-
istered daily in most studies but biweekly in others.3,6 Stud-
ies using higher numbers of stimuli obtained better results
than those using lower numbers. To capture the full poten-
tial of rTMS to reduce seizure frequency, we decided to
incorporate all factors that have been shown to be benefi-
cial, namely low-frequency stimulation targeting the epilep-
tic focus using neuronavigation, inclusion of patients with
well-delineated neocortical epilepsy, and a high number of
total stimuli during a treatment block.
A factor that has not been studied to date is whether
the effect of rTMS is influenced by the coil type used.
All studies with stimulation over the epileptic focus used
a figure-8 coil.4,6,8,10,12–14 With use of the figure-8 coil,
the maximal stimulation will occur near its center,
whereas with the round coil, inhibition of brain tissue sur-
rounding the center of the coil is expected. Both could be
effective, since epilepsy is not only a problem of hyper-
excitability of the focus but also of failure to prevent
spread to neighboring brain regions. It has been shown
that the round coil—when positioned over the focus—is
more effective than the figure-8 coil for aborting epileptic
discharges in patients with frontal lobe epilepsy.16 No
study to date, however, has evaluated the potential to
reduce seizures when targeting the epileptic focus with a
round coil. To investigate whether there are differences in
effect between the figure-8 and the round coil in individ-
ual patients, we performed a double-blind randomized
sham-controlled crossover clinical trial. The primary aim
of our study was to validate rTMS as a clinical tool to
treat selected patients with refractory neocortical epilepsy.
Methods
Participants
Eligible participants were 16–75 years old, with refrac-
tory focal epilepsy and a single epileptogenic zone, which
was determined during a presurgical investigation. Resec-
tion was not an option due to the proximity of eloquent cor-
tex or the patient declined surgery. The seizure frequency
was at least four per month and was recorded reliably in a
seizure diary by the patient or a caregiver. Antiepileptic
drugs (AEDs) were kept unchanged throughout the study.
Exclusion criteria were the exclusion criteria for TMS (in-
tracranial metal devices, pacemakers, ICDs, and so on),
nonepileptic seizures, rapidly progressive medical diseases,
suicidal ideation, pregnancy, and alcohol or drug abuse.
Patients were referred by epileptologists involved in multi-
disciplinary presurgical evaluation. No information about
the details of the randomization protocol was given to refer-
ring physicians. Previous failed epilepsy surgery was not an
exclusion criterion.
Study design
The trial utilized a prospective, randomized, double-blind
crossover design using three different coils to compare a fig-
ure-8 and round coil versus sham in each patient. The order
in which the three coils were used in each patient was ran-
domized using a computerized random number generator
and a permutation for each block of three patients. After
8 weeks of baseline evaluation on a stable drug dose,
patients underwent 2 weeks of stimulation (10 sessions)
with 1,500 stimuli a day at a frequency of 0.5 Hz, followed
by a 10-week observation period. Treatments were per-
formed in an outpatient setting, and sessions lasted about an
hour each day. This treatment was repeated twice, using the
figure-8 coil, the round coil, or the sham coil during the
treatment sessions. Patients were screened for inclusion by
one epileptologist (WVP). The treatment was always
administered by the same investigator (LS) who was blinded
to seizure count. Seizures diaries were checked by the study
nurse (AD) every 5 weeks and assessed by the epileptolo-
gist (WVP) at the end of each treatment period. Both asses-
sors were blinded to the order of the treatments. The study
nurse also systematically inquired about side effects after
each session.17 During baseline evaluation and at the end of
each observation period Quality Of Life In Epilepsy-31
(QOLIE-31),18 the Columbia Suicide Severity Rating Scale
(CSSRS), and global impression of change-scales were
rated. In order to assess if patients could be blinded in a
Key Points
• Low frequency rTMS is overall ineffective to reduce
seizure frequency in a 2-month period following active
treatment
• No difference was seen between treatments using a
figure-8 or a round coil positioned over the focus
• rTMS can cause rebound seizures after an initial
response
• rTMS can acutely exacerbate seizures
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satisfactory manner in a crossover trial, they were asked to
write down after the first day of each treatment block if they
thought a real or sham coil was used that day. These data
remained in a sealed envelope until all statistical analyses
were performed. The center of the ictal onset zone, as deter-
mined by the multidisciplinary epilepsy surgery team based
on magnetic resonance imaging (MRI), video-EEG, fluo-
rodeoxyglucose–positron emission tomography (FDG-
PET), and SISCOM data (Table 1, Fig. 1) was chosen as
the target to aim the center of the TMS coil. Neuronaviga-
tion using BrainSight (Rogue Research, Montreal, QC,
Canada) was used for coil placement, and continued feed-
back was used during the whole stimulation session. AMag-
stim Rapid2 (Magstim, Whitland, United Kingdom) was
used, with standard 70-mm figure-8 coil, a standard round
90-mm coil, and the commercially available sham coil.
Intensity was set as 90% of the resting motor threshold
(rMT), as determined at the onset of the study using the fig-
ure-8 coil. rMT was measured by first localizing the motor
hotspot by mapping a 5 9 5 cm area around the hand knob,
using neuronavigation, with electromyography (EMG)
recordings from the abductor pollicis brevis muscle (APB).
Intensity was first increased until motor evoked potentials
(MEPs) could be provoked to determine the hotspot. Next,
intensity was lowered in steps of 1% to determine the lowest
intensity needed to provoke 5/10 MEPs on EMG. We pre-
ferred this protocol to using a different intensity when using
the round coil or adapting the threshold each day, to mini-
mize chances of inadvertent unblinding of the patients. The
orientation of the coil was chosen so that it was perpendicu-
lar to the nearest important sulcus, as determined by a three-
dimensional (3D) reconstruction of the patients anatomic
brain MRI (Fig. 1). The choice between clockwise and
counterclockwise current flow with the round coil depended
on the hemisphere that was targeted and was based on the
optimal orientation for eliciting motor responses.19 The
1,500 stimuli a day were divided in three blocks, with short
breaks in between to allow for coil cooling and to check if
the neuronavigation system was still correctly calibrated.
All patients used foam earplugs (3M EARClassic). The trial
Figure 1.
Target of stimulation in individual patients, based on all available data of a presurgical workup. A miniature TMS coil is positioned over the
target of stimulation on a 3D rendering of the brain. The orientation of the coil during rTMS is illustrated. SISCOM hyperperfusion is visu-
alized in an orange color.
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was approved by the ethical committee of the University
Hospitals Leuven and registered as NCT01745952 on Clini-
calTrials.gov. Written informed consent was obtained from
all patients.
Statistical analysis methods
Based on a coefficient of variation equal to 1 derived
from data reported by Fregni et al.,10 29 patients were
needed to have at least 80% power to show a reduction of
50% between the active coil and the sham conditions based
on a two-sided t-test for lognormal data (since two compar-
isons are performed, alpha is set at 0.025). For the main
comparison of both coil conditions versus sham, 18 patients
were needed. These calculations were performed under the
worst case scenario of no correlation between the conditions
(i.e., no patient effect). Because it is reasonable to expect a
patient effect on the seizure rate, we aimed at including at
least 20 patients in the study. Recruitment was slower than
anticipated and, therefore, it was decided to terminate the
study before the planned number of subjects was included.
Note that the number of daily measurements per patient per
condition was large enough to guarantee at least 80% power
for the within-patient comparisons. First, for each patient
separately the number of seizures has been compared
between conditions with a Quasi-Poisson regression model
for count data followed by pairwise comparisons with
Tukey adjustments for multiple testing. Data were also
analyzed using negative binomial regression model as a
sensitivity analysis, since this model gives more weight to
lower counts. Second, the aggregated data over all ana-
lyzed patients were compared between conditions using a
negative binomial model with extra correction for overdis-
persion by adding a multiplicative overdispersion parame-
ter using Pearson chi-square statistics. The analysis on the
aggregated data did not take into account the within-
patient correlation between the different treatment condi-
tions. The analyses on patient level as well as on all
patients combined did not model the evolution over time
within each condition or the order of the treatment condi-
tions within a patient. An analysis of carryover effect was
planned but could not be performed due to small numbers.
A corrected p-value of 0.05 was considered significant.
Analyses have been performed using SAS software
(version 9.2, Windows).
Results
Study population
Fifteen patients were screened for inclusion, of which 11
agreed to participate (patients 1–11) (Fig. 2). Demographics
and clinical data of the randomized patients are given in
Table 1. Patients included in our study had refractory epi-
lepsy with a median of 24 seizures/month (range: 18/day to
2/month: one patient had lower seizure frequency than spec-
ified in inclusion criteria). They had failed on average 11
(3) AEDs and were taking three AEDs (range 1–5) during
the study. Four patients had undergone unsuccessful epi-
lepsy surgery, with incomplete resections near eloquent cor-
tex. Randomized patients were included from November
2012 until January 2014. The 11 randomized patients under-
went at least one full session of rTMS with the allocated coil
and kept a seizure diary during each 12-week treatment per-
iod. The data of one patient (patient 6) were not considered
for further analysis since the seizure diary did not include
the number of seizures per day on several occasions. Three
patients did not finish the whole protocol. Patient 1 was
excluded after the first session since the AED regimen was
changed due to toxicity. Patient 10 discontinued the study
after two treatment sessions, since she experienced the ses-
sions as painful and not effective. Data of the observation
period after the second (sham) treatment block were not
available. Patient 11 discontinued because of a fourfold
increase in seizure frequency during the second week of first
treatment session with a figure-8 coil (Fig. 3).
 
 
Eligible paents (n= 15) 
Excluded  (n= 4) 
- Not meeng inclusion criteria (n=1) 
- Declined to parcipate (n= 3) 
Analysis:  
- 1th session: n= 10         (pt 1-5, 7-11) 
- 2th & 3th session: n=7 (pt2-5, 7-9) 
- excluding one due to unreliable data (pt6) 
- including one paent who had a seizure 
frequency lower than prespeciﬁed in the 
protocol   (pt 9) 
Allocaon and follow up (n=11) 
Paents randomized (n=11) 
Received one treatment sessions (n=2)  
- Excluded aer change in AEDs due 
to toxicity (pt1) 
- Withdrawal of consent aer 
exacerbaon of seizures during ﬁrst 
treatment (pt11) 
Received two treatment sessions (n=1) 
- Disconnued due to lack of 
eﬃciency, reported “no change” 
aer both sessions, lost to follow-up 
aerwards (pt10) 
Received three treatment sessions (n=8) 
Figure 2.
CONSORT flowchart of recruitment and selection. AED, antiepi-
leptic drug; pt, patient. Patients were numbered in order of ran-
domization.
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Efficacy
No difference in mean seizure rate could be detected in
any of the conditions compared to baseline or between any
of the conditions. After corrections for differences in base-
line seizure count, results remained unchanged. Using a
negative binomial regression model resulted in the same
findings. To rule out an effect of shorter duration, a post hoc
analysis restricted to the first month of each condition was
performed. Again no change in average seizure frequency
was detected. Statistically significant changes in the seizure
frequency in individual patients between different treatment
conditions were seen in patients 4 and 8 (Table 2 and
Fig. 3). Patient 4 had a 18% seizure reduction after treat-
ment with a figure-8 coil, 48% seizure reduction after round
coil treatment, and a 44% reduction in the subsequent treat-
ment condition using the sham coil. In patient 8, worsening
in overall seizure frequency during the study period was sig-
nificant, despite a clinically meaningful weekly seizure fre-
quency reduction of >50% during the first month after each
active treatment. After this initial seizure frequency reduc-
tion, seizure frequency increased above the 95% confidence
interval (CI) of baseline seizure frequency during 18 weeks
following the reduction after the treatment with a round coil
(including the following period of sham treatment), and for
>20 weeks after treatment with the figure-8 coil (data not
shown in Fig. 3).
Secondary outcomemeasures
Seven patients were able to fill out questionnaires. The
baseline average quality of life based on the QOLIE-31 was
50/100 (with higher scores meaning better quality of life).
In three of six patients there was an improvement in QoL
with medium effect size20 after using the round coil, three of
five reported improvement after treatment with the figure-8
coil, and one of five after sham treatment. The latter patient
reported an improvement compared to baseline after each
treatment, with the smallest effect size after sham treatment.
One patient had worse scores after treatment with the round
and the sham coil. No relation with the treated hemisphere
was seen. No suicidal ideations were reported during the
study. When rating the global impression of change, five of
six patients reported no change after sham-treatment, four
of seven after figure-8 treatment, and five of eight after
treatment with the round coil. A moderate unfavorable evo-
lution was reported by three different patients after one
treatment session—sham, figure-8, and round coil treat-
ment, respectively. Patient 8 reported first a very favorable
response followed by an unfavorable one, as can be seen
also in the seizure evolution over time (Fig. 3, Table 2). We
checked allocation concealment by asking the patients to
guess the coil used in each session. For the first treatment
session, correct guessing of the allocated treatment was not
higher than could be expected by chance (Binomial test,
p = 0.26); for subsequent coils, patients could guess the
allocated treatment better than could be expected by chance.
Adverse events
The most important adverse effect noted in this study was
a negative effect on seizure frequency. In patient 8, there
was a clear increase in seizure frequency after an initial
reduction, and this increase was maintained up to 20 weeks
after the end of the study. This rebound in seizure frequency
was not a gradual process but rather an abrupt change from
one day to the next, and it was accompanied by severe head-
ache during 1 week in this patient with occipital epilepsy.
Patient 11 had a marked increase in seizure frequency dur-
ing the days of rTMS. Electroclinically these seizures were
comparable to the habitual seizures of the patient. The sei-
zures were more frequent during the actual stimulation and
in the hours following treatment. One patient experienced
hearing problems after stimulation, which was helped by
placing some pads between the ear and the coil. Four
patients experienced headache. Two patients experienced
fatigue with active treatment; two other patients experi-
enced fatigue with sham treatment. One patient reported dif-
ficulties concentrating. Side effects were minor according
to the patients, except in one patient in whom the headache
started within minutes of active treatment and felt like “the
operative scar was going to explode.”
Discussion
We report the data of a double-blind sham-controlled
crossover trial of low frequency rTMS in patients with
refractory neocortical epilepsy. We found no difference
between targeted rTMS over the focus using a figure-8 or a
round coil.
Surprisingly, our study demonstrated no overall effect
on seizure frequency using 0.5 Hz rTMS. This negative
finding for targeted rTMS using a figure-8 coil is in
contrast with the effect size of 0.71 (with a 95% CI at
0.30–1.12) in the meta-analysis of Hsu et al.15 and of
0.64 in the study of Sun et al.14 Our protocol was
designed to incorporate factors known to be associated
with a positive outcome: a 2-week 0.5 Hz paradigm at
an intensity 90% of rMT like the latter study combined
with detailed delineation of the focus including ictal
single-photon emission computed tomography (SPECT)12
and neuronavigation to position the coil.
Our protocol was most similar to the one described in the
study of Sun et al.,14 which is the largest study reporting
positive results to date. It is not described in their study how
many patients experienced a 50% seizure reduction, but the
number is probably high given that 11 of 31 patients in the
active treatment group were seizure-free at the end of the
8-week observation period. They used a custom-made fig-
ure-8 coil with 87 mm loops, whereas we used the Magstim
figure-8 coil with 70 mm loops. In their study, patients took
on average two AEDs, which is lower than three AEDs
taken in our patients’ sample. This could explain variable
responses to rTMS.21,22 The effect of a combination of
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Figure 3.
Evolution of weekly seizure frequency over time in individual patients.
Epilepsia ILAE
Epilepsia, **(*):1–10, 2015
doi: 10.1111/epi.13247
7
RCT of rTMS in Refractory Epilepsy
AEDs on the ability of rTMS to induce brain plasticity has
not been studied, but we speculate that high doses of
combined AEDs may limit the effect of rTMS to induce
synaptic alterations. Of note, the patient in our study who
experienced a transient improvement after both active coils
took only one AED.
An important determining factor for rTMS response is
the etiology of the epilepsy. Several other trials using rTMS
have been negative,2,4,6,7,9,11,12 but those trials often used
nonfocal stimulation2,7,9,11,12 and included patients with
both focal and multifocal epilepsy6,9,11,12 or neocortical and
mesial temporal epilepsy.2,4,7,9,11,12 Patients with mesial
temporal lobe epilepsy or multifocal epilepsy were, there-
fore, excluded from our study. Encephalomalacia was pre-
sent in 35% of the population of Sun et al.,14 but not in our
population. Fregni et al.8,10 reported positive results in two
trials in patients with polymicrogyria or nodular hetero-
topia. We included several patients with malformations of
cortical development, but not these subtypes. In addition,
procedural details can affect how the brain is stimulated in
otherwise identical protocols. One example is the way the
motor threshold is defined. Using neuronavigation and
EMG results in less chance to overestimate the rMT and
thus can lead to a lower intensity used for stimulation com-
pared to previous studies that relied on anatomic surface
markers.
Variability in rTMS response has also been ascribed to
age, gender, time of day, previous physical and mental
activity, genetic factors,23 brain states during stimula-
tion,24,25 short breaks in sessions,26 and corticospinal
excitability.27 Moreover, the effect on individual neurons
depends on their orientation relative to the induced electri-
cal field, and in epileptogenic lesions the architecture of the
neuronal elements can be different from that of other brain
regions. Part of the difference in response to rTMS between
our study and the study of Sun et al.14 might reflect reported
inherent neurophysiologic differences between Chinese and
Caucasians.28 This means that identical and seemingly
identical rTMS protocols can have varying effects on an
individual’s brain.
Even for well-established stimulation protocols over the
motor cortex, large variability is seen, with only 25–36% of
healthy subjects showing the expected changes in MEP
amplitudes in both directions.27,29
The variability in response in different studies using
rTMS can be explained at least partially by the small sample
sizes and variability in rTMS protocols in combination with
a large interindividual variability in response to TMS-
induced plasticity.
In our study, one patient experienced a >50% reduction in
seizure frequency during the month following each active
treatment, but afterwards a rebound phenomenon was
observed with a clear increase in seizure frequency. This
increased seizure frequency compared to baseline, was
maintained up to 20 weeks after the end of the study. This is
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to our knowledge the first report of rebound seizures after
successful treatment with rTMS. Moreover, our low-fre-
quency protocol exacerbated seizure frequency acutely in
one individual.
rTMS has been considered as a treatment that is well-tol-
erated when respecting the guidelines.30 We agree that this
is true in the majority of cases, but in patients with preexist-
ing allodynia over a scar from previously failed epilepsy
surgery, rTMS may be very painful. Half of our patients had
some improvement in QoL scores, consistent with the
observation that rTMS can influence psychological func-
tioning irrespective of seizure reduction.14 Improvement in
QoL was not dependent on the stimulated hemisphere. It has
to be noted that the QOLIE-31 questionnaire specifically
asked about the 4 weeks before administration of the ques-
tionnaire and we thus recorded changes occurring 8–
12 weeks after the first stimulation session. Our patient 8
had a significant improvement in QoL 1 month after treat-
ment, but not at the time when we administered the QoL
questionnaire.
Conclusion
We report the first pilot study of neuronavigated rTMS in
the treatment of focal neocortical epilepsy comparing a fig-
ure-8 and a round coil, but found no difference in efficacy.
To our surprise, we found no clear overall effect on seizure
frequency. We did see one acute exacerbation during active
treatment and one patient who responded during 1 month,
with deterioration afterward. Because our study was small
—as most rTMS studies in epilepsy—a large multicenter
trial will be needed to determine the position of neuronavi-
gated rTMS in the treatment of refractory focal neocortical
epilepsy.
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